Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ejso.2025.110321 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Nipocalimab: First Approval.
Drugs
September 2025
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Nipocalimab (nipocalimab-aahu; IMAAVY™) is a fully human monoclonal antibody that binds to and blocks the neonatal fragment crystallizable (Fc) receptor (FcRn) resulting in the reduction of circulating IgG levels. It is being developed by Johnson & Johnson for the treatment of a number of autoimmune disorders. On 29 April 2025, nipocalimab received its first approval in the USA for the treatment of generalized myasthenia gravis in adult and pediatric patients ≥ 12 years of age who are anti-acetylcholine receptor or anti-muscle specific tyrosine kinase antibody positive.
View Article and Find Full Text PDFComment on: "Muscle-specific strength predicts postoperative complications and survival in patients undergoing curative colectomy for colorectal cancer".
Eur J Surg Oncol
July 2025
Department of Colorectal and Anal Surgery, Gansu Provincial Central Hospital, No.999 Mogao Avenue, Anning District, Lanzhou, Gansu Province, 730070, China. Electronic address:
Application of array-based age prediction models to post-mortem tissue samples.
Forensic Sci Int Genet
January 2024
Department of Forensic Medicine, Seoul National University College of Medicine, Seoul, Korea; Institute of Forensic and Anthropological Science, Seoul National University College of Medicine, Seoul, Korea. Electronic address:
Article Synopsis
- Researchers studied DNA methylation patterns linked to age, using tissue samples to develop age prediction models.
- They collected 180 post-mortem samples from various tissues of 20 Koreans aged 18-78 and assessed their DNA methylation with the Infinium MethylationEPIC array.
- The pan-tissue epigenetic clock showed reasonable accuracy across all samples, while specific models like Hannum and MEAT excelled in predicting ages from blood and muscle tissues, respectively.
Rozanolixizumab: First Approval.
Drugs
September 2023
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Article Synopsis
- Rozanolixizumab (RYSTIGGO) is a humanized monoclonal antibody targeting the neonatal Fc receptor, developed by UCB Pharma for treating autoimmune diseases, particularly generalized myasthenia gravis (gMG).
- It received its first approval in the USA on June 27, 2023, specifically for adults with gMG who test positive for either anti-acetylcholine receptor (AChR) or anti-muscle-specific kinase (MuSK) antibodies.
- The drug is currently under regulatory review in the EU and Japan, and ongoing studies are exploring its effectiveness for other conditions like autoimmune encephalitis and severe fibromyalgia syndrome.
Reply to: Muscle-specific programmed cell death 5 in heart disease: Friend or foe?
Int J Cardiol
November 2022
Bio-X Institutes, Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders, Ministry of Education, Shanghai Jiao Tong University, Shanghai, China.